Liver failure

PTU-001 PROPRANOLOL AT MODEST DOSE DOES NOT IMPAIR SURVIVAL IN PATIENTS WITH CIRRHOSIS AND REFRACTORY ASCITES

doi:10.1136/gutjnl-2012-302514c.1

A E Robins,* A Bowden, W Watson, F Smith, W T Gelson, W J Griffiths. *Department of Hepatology, Cambridge University Hospitals, Cambridge, UK*

Introduction A recent study suggesting β -blockers should be contraindicated in cirrhotic patients with refractory ascites has gained significant attention.¹ We sought to examine this hypothesis in a cohort of patients undergoing elective paracentesis in a tertiary liver unit.

Methods We retrospectively studied 114 consecutive patients undergoing regular paracentesis between July 2007 and December 2010 at Addenbrooke's Hospital. 36 patients were maintained on propranolol for variceal prophylaxis, whereas 78 were not β -blocked. Mortality and morbidity were compared between the two groups. The χ^2 , Mann–Whitney and Kaplan–Meier methods were employed for statistical analysis.

Results There was no statistically significant difference between the two groups in terms of age, sex, aetiology of liver disease (predominantly alcohol), Child–Pugh score and UKELD. Hepatocellular carcinoma was present in 16% of patients in the propranolol group and 13% of the non β -blocked group ($p=0.62$). Varices were predictably present more in the propranolol group compared with the non β -blocked group (97% vs 59%, $p<0.001$). The mean total daily dose of propranolol used was 48.9 mg. The incidence of spontaneous bacterial peritonitis was similar between the propranolol group and non β -blocked group (43% vs 50%, $p=0.51$). The incidence of overt encephalopathy was also no different (43% vs 44%, $p=0.93$). Variceal bleeding occurred more frequently in the propranolol group compared with the non β -blocked group (69% vs 41%, $p<0.01$). Median survival was 18 months in the propranolol group vs 11 months in the non-propranolol group, with no significant difference between Kaplan–Meier survival curves ($p=0.93$, log rank test) (Abstract PTU-001 figure 1).

Abstract PTU-001 Figure 1 Kaplan–Meier survival curve.

Conclusion This study demonstrates that propranolol used in a total daily dose of between 40 and 80 mg is safe in patients with cirrhosis and refractory ascites. Deleterious effects at higher doses cannot be excluded. Notwithstanding this limitation and the retrospective nature of the analysis, these data reassure regarding the use of β -blockers in this patient group and that such drugs should not be immediately contraindicated.

Competing interests None declared.

REFERENCE

1. Serste T, Melot C, Francoz C, *et al*. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. *Hepatology* 2010;**52**:1017–22.

PTU-002 THE HEPATIC INFLAMMATORY MILIEU OF ACETAMINOPHEN INDUCED ACUTE LIVER FAILURE INDUCES ALTERNATIVELY ACTIVATED, M2-LIKE, MACROPHAGES

doi:10.1136/gutjnl-2012-302514c.2

^{1,2}C G Antoniadou,* ²V Zingarelli, ³L Possamai, ¹W Khamri, ¹N Vergis, ²R Mitry, ²A Quaglia, ²W Bernal, ²G Auzinger, ²Y Ma, ²J Wendon, ¹M Thursz. ¹Section of Hepatology, Imperial College London, London, UK; ²Institute of Liver Studies, King's College London, London, UK; ³Section of Hepatology, Imperial College Hospital, London, UK

Introduction Human acetaminophen-induced acute liver injury (AALF) is characterised by areas of hepatic necrosis that are infiltrated by macrophages (m ϕ) and elevated concentrations of anti-inflammatory cytokines. Anti-inflammatory mediators, such as secretory leucoprotease inhibitor (SLPI) and IL-10 contribute to the functional switching of m ϕ from a proinflammatory (M1) type to an alternatively activated (M2) phenotype that promotes tissue repair processes. We sought to determine the effects of the hepatic inflammatory milieu on peripheral monocytes (MO) and MO derived m ϕ in AALF.

Methods Phosphoflow technique was used to evaluate NF- κ Bp65, STAT-3 signalling pathways in ex-vivo MO in 10 AALF patients and 10 healthy controls (HC). Results expressed as MFI and ratio of activation. Regional changes (portal vein [PV], hepatic vein [HV]) were assessed in 5 AALF patients at time of transplantation. Serum (AALF [n=34]; HC [n=15]), hepatic (AALF [n=7]; HC [n=8]) and regional levels of TNF- α , IL-10 and SLPI were measured. The effect of the hepatic microenvironment was assessed in five cell culture experiments: purified CD14+ MO from HC were incubated with homogenates from AALF and culture medium (CM).

Results In MO, TLR-4 stimulation reduced NF- κ Bp65 expression in AALF compared to HC (0.8 vs 1.6; $p=0.001$). Ex-vivo STAT-3 expression was significantly elevated in AALF patients compared to HC (600 vs 232; $p=0.02$). AALF patients had higher serum concentrations of IL-10 (170 vs 40; $p<0.02$), SLPI (71200 vs 43310; $p<0.0001$) compared to HC. A trans-hepatic (HV>PV) gradient was seen for IL-10 and SLPI but not for TNF- α . Hepatic levels of IL-10 (2 vs 0.6; $p<0.02$) and SLPI (442 vs 116; $p<0.01$) were significantly elevated in AALF compared to HC tissue, with peak concentrations of IL-10 detected in necrotic areas while SLPI was highest in areas of hepatic regeneration. In vitro exposure to AALF milieu induced a unique CD14+CD16+ macrophage phenotype characterised increased expression of alternative (M2) activation markers- CD36 (78 vs 55%; $p=0.01$) and CD163 (58 vs 32.5%; $p=0.04$), reduced LPS-induced TNF- α (19.8 vs 40.5%; $p=0.02$), IL-6 (13.2 vs 22%; $p=0.04$) and enhanced phagocytosis (80.5 vs 70%; $p=0.03$) when compared to MO incubated CM.

Conclusion In AALF, circulating monocytes show modulations in intracellular signalling pathways compatible with anti-inflammatory responses. Our data also indicate that the anti-inflammatory hepatic microenvironment preferentially induces alternatively activated (M2)-like macrophages that may be implicated in resolution of acute liver injury.

Competing interests None declared.